Trials / Completed
CompletedNCT05201092
A Study Investigating Lu AG06466 in Healthy Men
Interventional, Open-Label, Single-Dose Study Investigating the Absorption, Metabolism and Excretion (AME) of Lu AG06466 Following Oral Dosing of 14C-Lu AG06466 to Healthy Men
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- Male
- Age
- 45 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate how the drug Lu AG06466 is absorbed, metabolized, and excreted from the body, for example, what the body does to the drug after swallowing a single dose.
Detailed description
Researchers will measure the levels of the drug and its breakdown product in each participants blood for up to 5 days after dosing. Radioactivity in urine and feces will be measured for up to 3.5 weeks after dosing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-Lu AG06466 | \[14C\]-Lu AG06466 will be administered per schedule specified in the arm description. |
Timeline
- Start date
- 2022-01-05
- Primary completion
- 2022-02-19
- Completion
- 2022-02-19
- First posted
- 2022-01-21
- Last updated
- 2022-03-16
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05201092. Inclusion in this directory is not an endorsement.